Mercer Global Advisors
VRDN icon

Mercer Global Advisors’s Viridian Therapeutics VRDN Stock Holding History

Mercer Global Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-875
Closed -$6K – 1183
2020
Q1 		$6K Buy
+875
New +$10.2K ﹤0.01% 1095

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
GPFA
Game Plan Financial Advisors Westlake, Ohio $222M AUM 22.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Mercer Global Advisors's VRDN Position: Q2 2020 in Review

Mercer Global Advisors sold out of Viridian Therapeutics (VRDN) in Q2 2020, closing a stake of 875 shares — an estimated $6K sold.

Mercer Global Advisors first reported a position in VRDN in Q1 2020 and held it in 1 quarter. The position peaked at $6K in Q1 2020. 28 funds tracked by Wall St. Rank hold VRDN as of Q2 2020.

  • Mercer Global Advisors reported no remaining Viridian Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Mercer Global Advisors sold 875 Viridian Therapeutics shares in Q2 2020, an estimated $6K.
  • Mercer Global Advisors first reported a position in Viridian Therapeutics in Q1 2020 and held it in 1 quarter.
  • Mercer Global Advisors's Viridian Therapeutics position peaked at $6K in Q1 2020.
  • 28 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2020.

Based on Mercer Global Advisors's 13F filing for Q2 2020, filed 10 Aug 2020.